875241-52-4

Basic information

• Product Name: 2-amino-4,6-dimethyl benzamide
• Synonyms: 2-amino-4,6-dimethyl benzamide
• CAS NO: 875241-52-4
• Molecular Weight: 164.207
• Mol File: 875241-52-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-amino-4,6-dimethyl benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-4,6-dimethyl benzamide(875241-52-4)
• EPA Substance Registry System: 2-amino-4,6-dimethyl benzamide(875241-52-4)

Safety Data

• Hazardous Substances Data: 875241-52-4(Hazardous Substances Data)

Upstream product

• 860683-36-9 4,6-dimethyl-2-nitrobenzamide 
• 90321-33-8 2-amino-4,6-dimethyl-benzoic acid 
• 35162-44-8 N-(3,5-dimethyl-phenyl)-2-hydroxyimino-acetamide 
• 49820-06-6 4,6-dimethyl-1H-indole-2,3-dione 
• 108-69-0 3,5-dimethylaminoaniline 
• 16618-56-7 2-chloro-1,5-dimethyl-3-nitro-benzene 
• 1635-84-3 2,4-Dimethyl-6-nitroanilin 
• 58579-99-0 2,4-dimethyl-6-nitro-benzonitrile 
• 10272-10-3 2-amino-4,6-dimethylbenzene-1,3-dicarbonitrile 

Downstream Products

• 1246250-87-2 2-(3,5-dimethyl-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-5,7-dimethylquinazolin-4(3H)-one 
• 1044871-11-5 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylquinazolin-4(3H)-one 
• 1044872-82-3 C₂₆H₃₆N₂O₃Si 

Relevant articles and documents

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.